Medical Oncology

Herbert Ira Hurwitz, MD

Adjunct Professor in the Department of Medicine
Campus mail 439 Seeley-Mudd Bldg, 10 Bryan Searle Drive, Duke University M, Durham, NC 27710
Phone (919) 681-6006
Email address hurwi004@mc.duke.edu

Particular Clinical Interests and Skills: Phase I clinical trials involving new anti cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system

Education and Training

  • Clinical Oncology Fellow, Medicine, Johns Hopkins University, 1992 - 1996
  • Medical Resident, Medicine, Michael Reese Hospital & Medical Center, 1988 - 1991
  • M.D., Thomas Jefferson University, 1988

Grants

Publications

Yaung, S. J., C. Ju, S. Gattam, A. Nicholas, N. Sommer, J. C. Bendell, H. I. Hurwitz, et al. “Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.” Cancers 14, no. 9 (May 1, 2022). https://doi.org/10.3390/cancers14092240.

Full Text

Mettu, Niharika B., Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, et al. “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.” Jama Netw Open 5, no. 2 (February 1, 2022): e2149040. https://doi.org/10.1001/jamanetworkopen.2021.49040.

PMID
35179586
Full Text

Strickler, John H., Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, et al. “Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.” Oncologist 26, no. 6 (June 2021): 465-e917. https://doi.org/10.1002/onco.13678.

PMID
33469991
Full Text

Lopes, Guilherme S., Christophe Tournigand, Curtis L. Olswold, Romain Cohen, Emmanuelle Kempf, Leonard Saltz, Richard M. Goldberg, et al. “Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials.” Clin Trials 18, no. 1 (February 2021): 51–60. https://doi.org/10.1177/1740774520959313.

PMID
32998522
Full Text

Yin, J., S. Dawood, R. Cohen, J. Meyers, J. Zalcberg, T. Yoshino, M. Seymour, et al. “Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.” Therapeutic Advances in Medical Oncology 13 (January 1, 2021). https://doi.org/10.1177/17588359211020547.

Full Text

Cremolini, Chiara, Carlotta Antoniotti, Alexander Stein, Johanna Bendell, Thomas Gruenberger, Daniele Rossini, Gianluca Masi, et al. “Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.” J Clin Oncol, August 20, 2020, JCO2001225. https://doi.org/10.1200/JCO.20.01225.

PMID
32816630
Full Text

Max Ma, Xiaoju, Johanna C. Bendell, Herbert I. Hurwitz, Christine Ju, John J. Lee, Alex Lovejoy, Christoph Mancao, et al. “Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.” Clin Cancer Res 26, no. 15 (August 1, 2020): 4010–17. https://doi.org/10.1158/1078-0432.CCR-19-1209.

PMID
32220893
Full Text

Garcia, Josep, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L. Coleman, Regula Deurloo, and Olivier L. Chinot. “Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.” Cancer Treat Rev 86 (June 2020): 102017. https://doi.org/10.1016/j.ctrv.2020.102017.

PMID
32335505
Full Text

Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.

PMID
31919136
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Pages